Sign In
Buy TRVI
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160 The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the fir
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
04:05pm, Tuesday, 03'rd Dec 2024
Statistically significant lower "Drug Liking" for the 81mg and 162mg doses of oral nalbuphine vs. butorphanol covering our clinical dose range Company to host a conference call and webcast today at 5:
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
07:30am, Thursday, 21'st Nov 2024
Corporate presentation will be held on Wednesday, December 4, 2024, at 1:00 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
04:05pm, Wednesday, 06'th Nov 2024
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chr
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
04:05pm, Wednesday, 30'th Oct 2024
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
07:30am, Monday, 21'st Oct 2024
Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn. , Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developin
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
07:30am, Tuesday, 15'th Oct 2024
NEW HAVEN, Conn. , Oct. 15, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
04:05pm, Thursday, 03'rd Oct 2024
Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) stud
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.
05:30pm, Monday, 30'th Sep 2024
NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
07:30am, Thursday, 26'th Sep 2024
Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER NEW HAVEN, Conn. , Sept. 26, 2024 /PRNewswire/ -- Tre
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
07:31am, Friday, 06'th Sep 2024
Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics NASD
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
04:05pm, Wednesday, 04'th Sep 2024
Professor Jacky Smith will present on the correlation between the change in objective cough count and improvement in patient-reported outcomes with nalbuphine ER in IPF patients NEW HAVEN, Conn. , Sep
Trevi Therapeutics to Participate in September Investor and Medical Conferences
07:30am, Wednesday, 28'th Aug 2024
NEW HAVEN, Conn. , Aug. 28, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript
01:28am, Sunday, 11'th Aug 2024
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - Chief Financial Officer David C
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
04:05pm, Thursday, 08'th Aug 2024
Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024 in th
